ClinicalTrials.gg
CompletedNCT06345755Updated Jul 14, 2025

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

A Phase 1 interventional study of VX-407 and Placebo in Autosomal Dominant Polycystic Kidney Disease (ADPKD), sponsored by Vertex Pharmaceuticals Incorporated. Completed at 2 sites in 2 countries. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-14.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jan 2025, 1 year 9 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
159
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States — 14 open to participants now, 25 under way, 1 of them phase 3. Polycystic Kidney, Autosomal Dominant · United States.

Enrollment
13th of 63
159 · median 48
Started
2024
with 2 others
Phase 1
10 of 85
2 open now
Registered
70th of 85
by date
Lead sponsor
6 of 85
Vertex Pharmaceuticals Incorporated

Among the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, this one is the 13th largest by enrollment of the 63 interventional ones that give a count, is one of 3 that started in 2024, is one of 10 in phase 1, and was the 70th registered.

Polycystic Kidney, Autosomal Dominant

185 studies on the registry are indexed under Polycystic Kidney, Autosomal Dominant; 42 are open to participants now.

Browse Polycystic Kidney, Autosomal Dominant studies →

Open to participants now

14 of the 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States are open now. Recruiting first, the newest first:

9 more — sign in →

All 14 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 30 Polycystic Kidney, Autosomal Dominant studies recruiting now, 8 (27%) set no upper age limit and 19 (63%) stop at 75 or younger; 7 take children under 18; 9 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 85 studies in Polycystic Kidney, Autosomal Dominant with a site in United States, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety, tolerability, and pharmacokinetic parameters of VX-407 in healthy participants.

Read the detailed description

This clinical trial information was submitted voluntarily under the applicable law and, therefore, certain submission deadlines may not apply. (That is, clinical trial information for this applicable clinical trial was submitted under section 402(j)(4)(A) of the Public Health Service Act and 42 CFR 11.60 and is not subject to the deadlines established by sections 402(j)(2) and (3) of the Public Health Service Act or 42 CFR 11.24 and 11.44.).

03

Conditions studied

  • Autosomal Dominant Polycystic Kidney Disease (ADPKD)
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • (BMI) of 18.0 to 32.0 kilogram per meter square (kg/m\^2)
  • A total body weight of greater than (>) 50 kg
  • Nonsmoker or ex-smoker for at least 3 months before screening

Key Exclusion Criteria:

  • History of febrile illness or other acute illness that has not fully resolved within 14 days before the first dose of study drug
  • Any condition possibly affecting drug absorption

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
159 participants (actual)

Study arms

  • Experimental
    Part A: Single Ascending Dose (SAD)

    Participants will be randomized to receive a single dose of different dose levels of VX-407.

    Drug: VX-407

  • Placebo comparator
    Part A: Placebo

    Participants will be randomized to receive placebo matched to VX-407.

    Drug: Placebo

  • Experimental
    Part B: Multiple Ascending Dose (MAD)

    Participants will be randomized to receive multiple doses of different dose levels of VX-407. The dose levels will be determined based on the data from Part A.

    Drug: VX-407

  • Placebo comparator
    Part B: Placebo

    Participants will be randomized to receive multiple doses of placebo matched to VX-407.

    Drug: Placebo

  • Experimental
    Part C: Drug-Drug Interaction

    Participants will be administered Midazolam (MDZ) in the presence or absence of VX-407. The dose levels will be determined based on the data from Part B.

    Drug: VX-407 · Drug: Midazolam

  • Experimental
    Part D

    Participants will be randomized to receive VX-407 in 1 of 3 treatment sequences with 3 dosing periods to assess the relative bioavailability of VX-407 formulations and the effect of food on the pharmacokinetics of VX-407.

    Drug: VX-407

Interventions

  • DrugVX-407

    Solution or Suspension for oral administration.

  • DrugPlacebo

    Solution or Suspension for oral administration.

  • Syrup for oral administration.

  • DrugVX-407

    Suspension or Tablets for oral administration.

06

What researchers measure

Primary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Enrollment up to Day 10

  2. Part B: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Enrollment up to Day 23

Secondary outcomes

  1. Part A: Maximum Observed Plasma Concentration (Cmax) of VX-407

    Time frame: From Day 1 up to Day 6

  2. Part B: Maximum Observed Plasma Concentration (Cmax) of VX-407

    Time frame: Days 1, 7, and 14

  3. Part A: Area Under the Concentration Versus Time Curve (AUC) of VX-407

    Time frame: From Day 1 up to Day 6

  4. Part B: Area Under the Concentration Versus Time Curve (AUC) of VX-407

    Time frame: Days 1, 7, and 14

  5. Part C: Area Under the Concentration Versus Time Curve (AUC) of MDZ in Absence and Presence of VX-407

    Time frame: On Day 1, and Day 15

  6. Part C: Maximum Observed Plasma Concentration (Cmax) of MDZ in Absence and Presence of VX-407

    Time frame: On Day 1, and Day 15

  7. Part C: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Enrollment up to Day 24

  8. Part D: Maximum Observed Plasma Concentration (Cmax) of VX-407 Tablet Formulation (test) compared to a Suspension Formulation (reference) Under Fasted Conditions

    Time frame: Days 1, 7, and 13

  9. Part D: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407 Under Fasted Conditions

    Time frame: Days 1, 7, and 13

  10. Part D: Maximum Observed Plasma Concentration (Cmax) of VX-407 Tablet Formulation Under Fed versus Fasted State

    Time frame: Days 1, 7, and 13

  11. Part D: Area Under the Concentration Versus Time Curve From the Time of Dosing Extrapolated to Infinity (AUC0-inf) of VX-407 Tablet Formulation Under Fed versus Fasted State

    Time frame: Days 1, 7, and 13

  12. Part D: Safety and Tolerability as Assessed by Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)

    Time frame: From Enrollment up to Day 22

07

Study locations

2 sites
  • ICON Lenexa
    Lenexa, Kansas 66219, United States
  • Altasciences Montreal
    Montreal, Canada
08

References and documents

Publications

  • Cortinovis M, Perico N, Remuzzi G. The Need for Novel Therapeutic Directions in Autosomal Dominant Polycystic Kidney Disease Patient Care. Clin J Am Soc Nephrol. 2025 Dec 5. doi: 10.2215/CJN.0000000975. Online ahead of print. PubMed 41348481 ↗

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2024 to primary completion in Jan 2025, 9 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 28, 2024
First posted
Apr 3, 2024
StartActual
Apr 17, 2024
Primary completionActual
Jan 27, 2025
CompletionActual
Jun 13, 2025
Last update
Jul 14, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 14, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06345755
Responsible party
Sponsor
First posted
Apr 3, 2024
Start date
Apr 17, 2024
Primary completion
Jan 27, 2025
Completion
Jun 13, 2025
Last update
Jul 14, 2025

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VX-407

Start the discussion